Stock Taper
TLSA
TIZIANA LIFE SCIENCES LTD
NASDAQ
$1.01
▼ DOWN 6.48% (-0.07)

KEY STATISTICS

Market Cap$64.27 M
52w High$2.35
52w Low$0.87
Dividend Yield
Frequency
P/E-3.19
Volume565.52K
Shares Out.63.63M

COMPANY

LEADERSHIP

Ivor R. Elrifi
CHIEF EXECUTIVE
Ivor R. Elrifi

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 20, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
10

UPCOMING EARNINGS

DateSep 18, 2026
DayFriday
Rev. Est.
SEP
18
FRI

SPLIT RECORD

DATETYPERATIO
2021-10-21Reverse1:2
2020-07-31Forward2499:1000
2019-10-29Forward2:1

PRICE

$1.01 ▼ DOWN 6.48% (−$0.07)
OVERLAYS
$1.00$1.02$1.03$1.059:32 AM10:37 AM11:41 AM12:45 PM1:50 PM2:55 PM3:59 PM1.01

About Tiziana Life Sciences Ltd

https://www.tizianalifesciences.com ↗

Tiziana Life Sciences Ltd is a UK-based biotech company developing therapies for oncology and immunology, including Foralumab, Milciclib, and anti-IL6R antibodies for diseases like Crohn’s, MS, cancer, and COVID-19.

INDUSTRY

Biotechnology

A PRODUCT TIZIANA LIFE SCIENCES LTD IS KNOWN FOR

Intranasal Foralumab
Intranasal Foralumab

Intranasal Foralumab, Tiziana Life Sciences' lead Phase 2 drug, is a nasal spray anti-CD3 antibody targeting neuroinflammation in diseases like SPMS and Alzheimer's.

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

DIRECTOR, 10 PERCENT OWNER:
CERRONE GABRIELE M
Purchase · 42.4K shares
2026-07-21
DIRECTOR, 10 PERCENT OWNER:
CERRONE GABRIELE M
Purchase · 15.0K shares
2026-06-12
OFFICER: CHIEF EXECUTIVE OFFICER
Elrifi Ivor
Purchase · 83.8K shares
2026-08-04
OFFICER: CHIEF EXECUTIVE OFFICER
Elrifi Ivor
Purchase · 237.6K shares
2026-08-05

SECTORS PEERS

PEERPRICE
IMMX$13.94COMPARE
ZNTL$3.80COMPARE
WHWK$4.62COMPARE
MGNX$4.13COMPARE
COYA$4.59COMPARE
PLRX$1.11COMPARE
EXOZ$7.17COMPARE
OKYO$1.67COMPARE